Results
1 -
10 of
108Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development, Molecular Cancer Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma, Biomarker Research PI3K?? isoform-dependent activation of RhoA regulates Wnt5a-induced osteosarcoma cell migration, Cancer Cell International Inhibiting PI3K as a therapeutic strategy against cancer, Clinical and Translational Oncology Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K in a cell-type-dependent manner to induce lipogenesis-dependent epithelialu2013mesenchymal transition through the regulation of ADAM10 and ADAM17, Molecular and Cellular Biochemistry Novel Agents in Hodgkin Lymphoma, Current Oncology Reports Towards Targeted Therapy of Chronic Lymphocytic Leukemia, Advances in Chronic Lymphocytic Leukemia The CLL Cell Microenvironment, Advances in Chronic Lymphocytic Leukemia PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL), B Cell Receptor Signaling